Supernus Pharmaceuticals Inc (SUPN) Q4 2025 Earnings Call Transcript

Why It Matters

The results highlight Vanda’s ability to grow its core psychiatry franchise while navigating significant tax and cash‑flow pressures, and the tradipitant approval opens a sizable new market that could diversify earnings.

Key Takeaways

• Fanapt sales up 25% YoY, driven by bipolar launch
• Tradipitant approved for motion sickness, first oral in 40 years
• Cash down to $263.8M, net loss $120.5M after tax charge
• HETLIOZ sales decline as generics erode market share
• 2026 revenue guidance $230‑$260M, excludes new product launches

Pulse Analysis

Vanda’s 2025 earnings underscore the power of focused commercial execution in the psychiatric space. Fanapt, the company’s flagship antipsychotic, delivered a 25% year‑over‑year revenue increase, buoyed by a 36% rise in total prescriptions and a striking 108% surge in new‑to‑brand fills. The expansion of the sales force—from roughly 160 to 300 representatives—amplified face‑to‑face outreach, translating prescription volume into tangible top‑line growth. Meanwhile, the HETLIOZ franchise continued to feel pressure from generic competition, with sales slipping despite retaining a dominant U.S. market share, illustrating the challenges of sustaining legacy products in a crowded therapeutic arena.

Regulatory milestones added a forward‑looking catalyst to Vanda’s pipeline. The FDA’s approval of tradipitant (branded Nirius) for motion‑sickness prevention introduces the first oral therapy in over forty years, targeting a market where 25‑30% of U.S. adults experience symptoms. The drug’s potential label expansion into GLP‑1‑induced vomiting could tap the burgeoning diabetes and obesity treatment segment, further diversifying revenue streams. Concurrently, the melperone (Vasanti) NDA is under review with a PDUFA date of February 21, 2026, and the imsidolimab BLA advances toward approval for generalized pustular psoriasis, positioning Vanda for growth across psychiatry, gastroenterology, and dermatology.

Financially, the company’s balance sheet reflects the cost of aggressive expansion. Operating expenses rose by $128 million, driven by higher SG&A spend on launches and R&D for late‑stage candidates such as desipramine and iloperidone LAI. A non‑cash tax valuation allowance inflated the net loss, while cash on hand dropped to $263.8 million, prompting management to warn of higher cash burn in 2026. Nonetheless, the firm’s revenue guidance of $230‑$260 million, excluding anticipated contributions from Nirius and Vasanti, signals confidence in its existing portfolio’s ability to sustain growth amid ongoing investment in pipeline development and commercial infrastructure.